The street.com asserts that inhaled insulin isn't popular.

The nascent commercial launch of Afrezza continues to resemble a train wreck. MannKind's signature product contributed only €2 million to Sanofi's sales in the third quarter. That's flat with second quarter sales despite Sanofi's upgraded efforts to convince U.S. doctors to prescribe the inhaled insulin to their diabetes patients. Through nine months of 2014, Afrezza sales have totaled €5 million, well below Sanofi's expectations.